Live Breaking News & Updates on Marinus pharmaceuticals inc

Stay informed with the latest breaking news from Marinus pharmaceuticals inc on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Marinus pharmaceuticals inc and stay connected to the pulse of your community

Marinus Pharma (MRNS) Comments on Patent Challenge by Ovid, Provides Update on Marinus' Post Grant Review

Marinus Pharma (MRNS) Comments on Patent Challenge by Ovid, Provides Update on Marinus' Post Grant Review
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Scott-braunstein , Nasdaq , Patent-office , Marinus-pharmaceuticals-inc , Ovid-therapeutics-inc , Marinus-pharmaceuticals , Inter-partes-review , Ovid-therapeutics , Marinu-phase , Patent-trial , Appeal-board ,

HC Wainwright Reiterates "Buy" Rating for Marinus Pharmaceuticals (NASDAQ:MRNS)

HC Wainwright Reiterates "Buy" Rating for Marinus Pharmaceuticals (NASDAQ:MRNS)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Canada , Hedge-funds-weigh-in-on-marinus-pharmaceuticals , Charles-schwab-investment-management-inc , Goldman-sachs-group-inc , Marinus-pharmaceuticals-trading , Analyst-recommendations-for-marinus-pharmaceuticals , Royal-bank , Renaissance-technologies , Marinus-pharmaceuticals-inc , News-ratings-for-marinus-pharmaceuticals-daily , Metlife-investment-management

Oppenheimer Reiterates Market Perform Rating for Marinus Pharmaceuticals (NASDAQ:MRNS)

Oppenheimer Reiterates Market Perform Rating for Marinus Pharmaceuticals (NASDAQ:MRNS)
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Canada , Wellington , New-zealand-general- , New-zealand , Marinus-pharmaceuticals , Royal-bank , Marinus-pharmaceuticals-stock , Wellington-management-group , Marinus-pharmaceuticals-inc , Nuveen-asset-management , Barclays-plc

Marinus Pharmaceuticals (NASDAQ:MRNS) Downgraded by StockNews.com to Sell

StockNews.com downgraded shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) from a hold rating to a sell rating in a research note issued to investors on Wednesday. Several other brokerages also recently weighed in on MRNS. Truist Financial cut their price target on Marinus Pharmaceuticals from $32.00 to $25.00 and set a buy rating on […]

Canada , Life-insurance-co , Marinus-pharmaceuticals-stock-performance , Marinus-pharmaceuticals-inc , Royal-bank , News-ratings-for-marinus-pharmaceuticals-daily , Tower-research-capital , Marinus-pharmaceuticals , Charles-schwab-investment-management-inc , Nuveen-asset-management , Deutsche-bank

Marinus Pharmaceuticals' (MRNS) Outperform Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada reissued their outperform rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) in a research note released on Wednesday morning, Benzinga reports. They currently have a $24.00 target price on the biopharmaceutical company’s stock. A number of other research analysts have also recently commented on the stock. Truist Financial cut […]

Canada , Institutional-trading-of-marinus-pharmaceuticals , Marinus-pharmaceuticals-inc , Ameritas-investment-partners-inc , Marinus-pharmaceuticals-trading , Marinus-pharmaceuticals , Royal-bank , Nasdaq , Analyst-recommendations-for-marinus-pharmaceuticals , News-ratings-for-marinus-pharmaceuticals-daily , Bluepath-capital-management

Marinus Pharmaceuticals (NASDAQ:MRNS) Cut to Sell at StockNews.com

StockNews.com lowered shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) from a hold rating to a sell rating in a research note released on Wednesday morning. MRNS has been the subject of several other reports. Truist Financial reduced their target price on shares of Marinus Pharmaceuticals from $32.00 to $25.00 and set a buy rating […]

Canada , Blackrock , Nova-scotia , Lion-point , Northwest-territories , Institutional-trading-of-marinus-pharmaceuticals , Marinus-pharmaceuticals-stock , Marinus-pharmaceuticals , Analyst-recommendations-for-marinus-pharmaceuticals , Marinus-pharmaceuticals-inc , Blackrock-inc

Marinus Pharmaceuticals (NASDAQ:MRNS) Shares Down 7.4%

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Free Report) dropped 7.4% on Tuesday . The stock traded as low as $9.20 and last traded at $9.22. Approximately 137,536 shares changed hands during mid-day trading, a decline of 63% from the average daily volume of 372,639 shares. The stock had previously closed at $9.96. Wall Street Analyst […]

United-states , American , Nasdaq , Marinus-pharmaceuticals-inc , Financial-group , Jennison-associates , News-ratings-for-marinus-pharmaceuticals-daily , Harvest-investment-services , Marinus-pharmaceuticals , York-mellon-corp , Marinus-pharmaceuticals-stock-down

Analysts Set Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Target Price at $20.44

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Free Report) have earned an average rating of “Moderate Buy” from the eight brokerages that are covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month target price […]

Marinus-pharmaceuticals-inc , Nasdaq , Charles-schwab-investment-management-inc , Goldman-sachs-group-inc , Hedge-funds-weigh-in-on-marinus-pharmaceuticals , Marinus-pharmaceuticals , Analyst-recommendations-for-marinus-pharmaceuticals , Marinus-pharmaceuticals-stock-down , Marinus-pharmaceuticals-company-profile , News-ratings-for-marinus-pharmaceuticals-daily , Metlife-investment-management

Marinus Pharmaceuticals to Present at Upcoming Investor Conferences

Marinus Pharmaceuticals, Inc. , a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will present at and...

Boston , Massachusetts , United-states , Marinus-pharmaceuticals-inc , Marinus-pharmaceuticals , Nasdaq , Panel-discussion , Annual-healthcare-conference , Orphan-epilepsies , Biopharma-conference , Markets

Marinus Pharmaceuticals (NASDAQ:MRNS) Trading Down 7.4%

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS – Get Free Report) dropped 7.4% during trading on Tuesday . The company traded as low as $9.20 and last traded at $9.22. Approximately 137,536 shares were traded during mid-day trading, a decline of 63% from the average daily volume of 372,639 shares. The stock had previously closed at […]

Bluepath-capital-management , Nasdaq , Marinus-pharmaceuticals-inc , Institutional-trading-of-marinus-pharmaceuticals , Marinus-pharmaceuticals-stock-down , Life-insurance-co , Ameritas-investment-partners-inc , News-ratings-for-marinus-pharmaceuticals-daily , Marinus-pharmaceuticals-company-profile , Marinus-pharmaceuticals , Get-free-report